Showing results (921-930 of 951) with videos related to
Sort By:
Pageof 96
The Lancet. Infectious Diseases|October 23, 2022
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trialShabir A Madhi, Gaurav Kwatra, Simone I Richardson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2021
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE TrialHannah L Rush, Laura Murphy, Alicia K Morgans, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|June 17, 2014
Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populationsDomtila Kimani, Ya Jankey Jagne, Momodou Cox, et al.Journal of Virological Methods|January 25, 2022
Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utilityCarolina Rosadas, Maryam Khan, Eleanor Parker, et al.Annals of the New York Academy of Sciences|October 2, 2022
Lessons from the pandemic: Responding to emerging zoonotic viral diseases-a Keystone Symposia reportJennifer Cable, Anthony Fauci, William E Dowling, et al.Lancet (London, England)|September 4, 2021
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)Amy Flaxman, Natalie G Marchevsky, Daniel Jenkin, et al.Clinical and Experimental Immunology|February 2, 2023
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trialsMerryn Voysey, Amy Flaxman, Jeremy Aboagye, et al.Nature|July 31, 2020
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaquesNeeltje van Doremalen, Teresa Lambe, Alexandra Spencer, et al.The Lancet. HIV|August 20, 2021
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trialShabir A Madhi, Anthonet L Koen, Alane Izu, et al.NPJ Vaccines|July 23, 2025
Nipah virus vaccines evaluated in pigs as a 'One Health' approach to protect public healthRebecca K McLean, Miriam Pedrera, Nazia Thakur, et al.Pageof 96